Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences